Barclays PLC Acquires 216,757 Shares of Sutro Biopharma, Inc. (NASDAQ:STRO)

Barclays PLC grew its holdings in shares of Sutro Biopharma, Inc. (NASDAQ:STROFree Report) by 385.3% during the third quarter, Holdings Channel.com reports. The institutional investor owned 273,019 shares of the company’s stock after purchasing an additional 216,757 shares during the quarter. Barclays PLC’s holdings in Sutro Biopharma were worth $944,000 at the end of the most recent quarter.

Several other large investors also recently modified their holdings of STRO. Geode Capital Management LLC lifted its position in shares of Sutro Biopharma by 7.7% during the 3rd quarter. Geode Capital Management LLC now owns 1,856,956 shares of the company’s stock valued at $6,426,000 after acquiring an additional 132,015 shares during the period. XTX Topco Ltd increased its stake in Sutro Biopharma by 222.0% in the third quarter. XTX Topco Ltd now owns 104,200 shares of the company’s stock valued at $361,000 after purchasing an additional 71,844 shares in the last quarter. Jane Street Group LLC raised its holdings in shares of Sutro Biopharma by 30.7% during the third quarter. Jane Street Group LLC now owns 108,192 shares of the company’s stock valued at $374,000 after purchasing an additional 25,416 shares during the period. State Street Corp boosted its position in shares of Sutro Biopharma by 5.2% during the 3rd quarter. State Street Corp now owns 1,647,162 shares of the company’s stock worth $5,699,000 after purchasing an additional 81,855 shares in the last quarter. Finally, BNP Paribas Financial Markets grew its stake in shares of Sutro Biopharma by 1,195.1% in the 3rd quarter. BNP Paribas Financial Markets now owns 82,524 shares of the company’s stock valued at $286,000 after buying an additional 76,152 shares during the period. Institutional investors and hedge funds own 96.99% of the company’s stock.

Sutro Biopharma Price Performance

STRO opened at $1.72 on Wednesday. Sutro Biopharma, Inc. has a 1 year low of $1.67 and a 1 year high of $6.13. The company has a market capitalization of $141.83 million, a price-to-earnings ratio of -1.07 and a beta of 1.15. The firm’s fifty day moving average price is $2.56 and its two-hundred day moving average price is $3.37.

Analyst Upgrades and Downgrades

STRO has been the topic of a number of research reports. HC Wainwright reaffirmed a “buy” rating and set a $12.00 price target on shares of Sutro Biopharma in a research note on Monday, November 18th. Piper Sandler reaffirmed an “overweight” rating and set a $11.00 target price on shares of Sutro Biopharma in a research report on Friday, October 11th. JMP Securities reissued a “market outperform” rating and issued a $17.00 price target on shares of Sutro Biopharma in a research report on Wednesday, December 11th. Wells Fargo & Company decreased their price target on shares of Sutro Biopharma from $5.00 to $4.00 and set an “equal weight” rating for the company in a research note on Wednesday, December 11th. Finally, Wedbush reaffirmed an “outperform” rating and issued a $8.00 price objective on shares of Sutro Biopharma in a research note on Tuesday, December 10th. One equities research analyst has rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $11.13.

Check Out Our Latest Stock Analysis on Sutro Biopharma

Sutro Biopharma Company Profile

(Free Report)

Sutro Biopharma, Inc operates as a clinical-stage oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. Its product candidates include STRO-002, an ADC directed against folate receptor-alpha, which is in Phase II/III clinical trials for patients with ovarian and endometrial cancers; VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and MK-1484, a distinct cytokine derivative molecule that is in Phase I clinical study for the treatment of cancer.

Featured Stories

Want to see what other hedge funds are holding STRO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sutro Biopharma, Inc. (NASDAQ:STROFree Report).

Institutional Ownership by Quarter for Sutro Biopharma (NASDAQ:STRO)

Receive News & Ratings for Sutro Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sutro Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.